Volume 5 Issue 2
Dec.  2021
Turn off MathJax
Article Contents
Fanghao Liu, Haoyu Li, Yunfeng Miao, Guoli Lv. Treatment of stage IIIB squamous-cell lung cancer with pembrolizumab combined with chemotherapy to achieve pCR: a case report[J]. Blood&Genomics, 2021, 5(2): 149-153. doi: 10.46701/BG.2021022021121
Citation: Fanghao Liu, Haoyu Li, Yunfeng Miao, Guoli Lv. Treatment of stage IIIB squamous-cell lung cancer with pembrolizumab combined with chemotherapy to achieve pCR: a case report[J]. Blood&Genomics, 2021, 5(2): 149-153. doi: 10.46701/BG.2021022021121

Treatment of stage IIIB squamous-cell lung cancer with pembrolizumab combined with chemotherapy to achieve pCR: a case report

doi: 10.46701/BG.2021022021121
More Information
  • Corresponding author: Guoli Lv, Department of Geriatric Thoracic Surgery, the First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, China. E-mail: lvguoli2009@163.com
  • Received Date: 2021-06-28
  • Accepted Date: 2021-12-08
  • Rev Recd Date: 2021-11-24
  • Available Online: 2022-01-06
  • Publish Date: 2021-12-31
  • Lung cancer is currently the leading cause of global cancer-related deaths and its incidence increases every year. Most squamous-cell lung cancers are in the advanced stage at diagnosis. This study reported a case of a 66-year-old man diagnosed with unresectable stage IIIB squamous-cell lung cancer (cT2aN3M0), who was treated with pembrolizumab combined with paclitaxel (albumin-bound) + nedaplatin. After four cycles, a follow-up chest computed tomography (CT) scan showed the disappearance of the original right lower lobe lung mass with cavitation-like changes, and a follow-up chest CT scan 6w later revealed a solid nodule measuring approximately 1.5 cm in diameter within the cavity. Subsequent surgical excision of the residual primary lesion was performed to achieve complete pathological remission. The patient was treated with pembrolizumab combined with paclitaxel (albumin-bound) + nedaplatin and achieved complete pathological remission with surgical excision.

     

  • loading
  • [1]
    Wild CP, Weiderpass E, Stewart BW. World cancer report: cancer research for cancer prevention[R]. Lyon: International Agency for Research on Cancer, 2020. https://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-Cancer-Research-For-Cancer-Prevention-2020.
    [2]
    Hsu ML, Naidoo J. Principles of immunotherapy in non-small cell lung cancer[J]. Thorac Surg Clin, 2020, 30(2): 187−198. doi: 10.1016/j.thorsurg.2020.01.009
    [3]
    Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med, 2018, 379(21): 2040−2051. doi: 10.1056/NEJMoa1810865
    [4]
    Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer[J]. N Engl J Med, 2018, 378(22): 2078−2092. doi: 10.1056/NEJMoa1801005
    [5]
    Socinski MA, Obasaju C, Gandara D, et al. Current and emergent therapy options for advanced squamous-cell lung cancer[J]. J Thorac Oncol, 2018, 13(2): 165−183. doi: 10.1016/j.jtho.2017.11.111
    [6]
    Bar J, Urban D, Ofek E, et al. Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): updated report of a phase I study, MK3475-223[J]. J Clin Oncol, 2019, 37(15_suppl): 8534−8534. doi: 10.1200/JCO.2019.37.15_suppl.8534
    [7]
    Hill A, Gong J, Wilczynski S, et al. Complete pathologic response when adding pembrolizumab to neoadjuvant chemotherapy in Stage IIIA non-small-cell lung cancer[J]. J Oncol Pract, 2018, 14(9): 569−571. doi: 10.1200/JOP.18.00127
    [8]
    Tanvetyanon T, Gray JE, Antonia SJ. PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer[J]. Expert Opin Biol Ther, 2017, 17(3): 305−312. doi: 10.1080/14712598.2017.1280454
    [9]
    Rhodin KE, Rucker AJ, Ready NE, et al. The immunotherapeutic landscape in non-small cell lung cancer and its surgical horizons[J]. J Thorac Cardiovasc Surg, 2019, 159(4): 1616−1623. doi: 10.1016/j.jtcvs.2019.08.138
    [10]
    Baek J, Owen DH, Merritt RE, et al. Minimally invasive lobectomy for residual primary tumors of advanced non-small-cell lung cancer after treatment with immune checkpoint inhibitors: case series and clinical considerations[J]. Clin Lung Cancer, 2020, 21(4): e265−e269. doi: 10.1016/j.cllc.2020.02.016
    [11]
    Provencio-Pulla M, Nadal-Alforja E, Cobo M, et al. Neoadjuvant chemo/immunotherapy for the treatment of stages IIIA resectable non-small cell lung cancer (NSCLC): a phase Ⅱ multicenter exploratory study-NADIM study-SLCG[J]. J Clin Oncol, 2018, 36(15_suppl): 8521. doi: 10.1200/JCO.2018.36.15_suppl.8521
    [12]
    Rizk EM, Chen A, Silverman AM, et al. Abstract 2798: High density of CD68+ HLA-DR- macrophages in the stroma of primary melanoma correlates with an unfavorable immune microenvironment as assessed by digital spatial profiling[J]. Tumor Biol, 2019, 79(13): 2798. doi: 10.1158/1538-7445.AM2019-2798
    [13]
    Mazzaschi G, Facchinetti F, Missale G, et al. The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC[J]. Lung Cancer, 2019, 127: 153−163. doi: 10.1016/j.lungcan.2018.11.038
    [14]
    Barroso-Sousa R, Barry WT, Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(2): 173−182. doi: 10.1001/jamaoncol.2017.3064
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(1)

    Article Metrics

    Article views (138) PDF downloads(9) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return